Asberger Jasmin, Ge Isabell, Schmidt Benjamin, Jäger Markus, Weiss Daniela, Berner Kai, Erbes Thalia, Juhasz-Böss Ingolf, Mayer Sebastian
Department of Obstetrics and Gynecology, Medical Center, University of Freiburg, D-79106 Freiburg, Germany.
Faculty of Medicine, University of Freiburg, D-79110 Freiburg, Germany.
Exp Ther Med. 2025 Jan 22;29(3):54. doi: 10.3892/etm.2025.12804. eCollection 2025 Mar.
Breast cancer represents the most common type of cancer in females worldwide. The survival rates for breast cancer patients have been increasing since 1990. However, in 2023 breast cancer is still the second most common cause of malignancy-associated death in women. One decisive reason is the increase of treatment resistance and low therapy response. Therefore, new therapy targets and predictive markers for the response to treatment are needed. The present study analyzed the potential effects triggered by different breast cancer treatments on the transcriptional expression of 12 pre-selected long non-coding (lnc) RNAs and the proliferation markers Cyclin D1 and Ki-67 in six different breast cancer cell lines (BT-474, MDA-MB-231, BT-20, T-47D, SKBR-3 and MCF-7). The results revealed that lncRNA cytoskeleton regulator RNA may be an appropriate biomarker for the response to treatment with both epirubicin and gemcitabine (P<0.001). NF-ĸB interacting lnc RNA may be a marker for therapy response (P<0.001), while HOX transcript antisense RNA overexpression suggested resistance to treatment (P<0.001) with epirubicin. The transcriptional expression of lncRNA BC4 increased during treatment with epirubicin and gemcitabine, which indicated therapy response. Overall, the present data suggested that the aforementioned lncRNAs have a promising potential as biomarkers to detect early therapy response or resistance in and therefore should be analyzed in more detail.
乳腺癌是全球女性中最常见的癌症类型。自1990年以来，乳腺癌患者的生存率一直在上升。然而，在2023年，乳腺癌仍是女性恶性肿瘤相关死亡的第二大常见原因。一个决定性原因是治疗耐药性的增加和治疗反应较低。因此，需要新的治疗靶点和治疗反应预测标志物。本研究分析了六种不同乳腺癌细胞系（BT-474、MDA-MB-231、BT-20、T-47D、SKBR-3和MCF-7）中不同乳腺癌治疗对12种预先选择的长链非编码（lnc）RNA以及增殖标志物细胞周期蛋白D1和Ki-67转录表达的潜在影响。结果显示，lncRNA细胞骨架调节RNA可能是表柔比星和吉西他滨治疗反应的合适生物标志物（P<0.001）。NF-κB相互作用lnc RNA可能是治疗反应的标志物（P<0.001），而HOX转录本反义RNA的过表达提示对表柔比星治疗耐药（P<0.001）。在表柔比星和吉西他滨治疗期间，lncRNA BC4的转录表达增加，这表明有治疗反应。总体而言，目前的数据表明，上述lncRNAs作为检测早期治疗反应或耐药性的生物标志物具有广阔的潜力，因此应进行更详细的分析。
